Human VCAM1 adenoviral particles

Vascular cell adhesion molecule 1 (VCAM1) is a key gene encoding a cell surface glycoprotein that plays a key role in inflammatory and immune responses. VCAM1 is primarily expressed on endothelial cells, macrophages, and certain epithelial cells and mediates leukocyte recruitment by interacting with integrins, particularly α4β1 (VLA-4). This interaction promotes leukocyte adhesion and migration within endothelial cells, a process that is critical for immune surveillance and pathological states such as atherosclerosis, autoimmune diseases, and chronic inflammation. The VCAM1 gene is regulated by proinflammatory cytokines such as TNF-α and IL-1β, making it a key biomarker and therapeutic target for inflammatory diseases. Its involvement in cell signaling and immune regulation underscores its importance in biomedical research and drug development. Human VCAM1 adenoviral particles are engineered viral vectors designed to deliver the VCAM1 gene to target cells for expression. These particles take advantage of the high transduction efficiency and broad tropism of adenoviruses to enable robust gene delivery in both dividing and non-dividing cells, including primary endothelial cells and immune cells. The recombinant adenovirus carries full-length or truncated human VCAM1 cDNA and is controlled by a strong promoter, ensuring high levels of expression required for functional studies. Researchers use these particles to study the role of VCAM1 in leukocyte adhesion, endothelial cell activation, and inflammatory pathways, and to develop gene therapy strategies for vascular diseases.